ArriVent to Present Phase 1 Data for ARR-217 at ESMO Congress
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
ArriVent BioPharma announced it will present initial Phase 1 data for its targeted cancer therapy ARR-217 at the ESMO Congress in Madrid in October 2026.
- The rapid oral presentation will cover safety and efficacy data in patients with gastrointestinal cancers.
- The ongoing clinical trial evaluates the CDH17-targeted antibody-drug conjugate.
- The company will host a virtual webinar on October 26, 2026, to discuss the findings.
Covered by 3 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
Timeline
First to report: Globenewswire_fr (); 3 articles from 2 outlets so far.
Who is covering this story
- Center (2): Globenewswire_fr, PR Newswire Asia
Sources
- ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 — Globenewswire_fr (center, AI-estimated) ·
- ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 — Globenewswire_fr (center, AI-estimated) ·
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer — PR Newswire Asia (center, AI-estimated) ·